BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August

FDA meeting scheduled in August and is intended to support potential sNDA submission for label expansion of IGALMI^® in the at-home setting

Read more at globenewswire.com